Good manufacturing practice production of adenoviral vectors for clinical trials.
about
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogensMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.The Effect of CXCR4 Overexpression on Mesenchymal Stem Cell Transplantation in Ischemic Stroke.Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.Innate immunity to adenovirus.Downstream processing of cell culture-derived virus particles.Adenoviral producer cellsCancer immunotherapy: a paradigm shift for prostate cancer treatment.Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.Human amniocyte-derived cells are a promising cell host for adenoviral vector production under serum-free conditions.Bioprocess development for canine adenovirus type 2 vectors.In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease.Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose
P2860
Q26750912-DE8148E4-B97F-4007-B419-555FEE314620Q26752807-16911044-935D-4741-A875-C4F4F123CCB4Q27013568-00D4F348-6424-429D-B586-D445C3EB8828Q30226988-893238CE-1AAB-44AE-81FB-B69652624211Q33930161-44D04B51-EECE-4BE0-A8C3-E418E66F2691Q36523465-29B6FCCF-9EE2-4C55-B098-9638539E59F8Q37310677-E55FD2BB-1DB7-4752-A1BD-ECAE14D3F7A7Q37448942-C500A21A-16A7-4998-B758-A0FD09D1477BQ37718852-7015499C-FD9B-4E2C-953F-CF7AE0FDE27CQ37944322-6BDB8EEB-8DB8-4ABC-A62C-17A18B1E434DQ37945217-64BFC144-5626-4E4A-9200-2E26FCA52C86Q38013964-F51ED785-1681-406C-A797-3B6848ECF713Q38443390-67EE0254-725C-444D-97D0-93B95EA1A910Q38878799-47F93875-25B6-4232-9949-4E622D393AC6Q39319692-EECF232B-FE2B-4120-B9ED-135887DBA3A2Q47553772-23F32D4B-AE54-4B2B-9EA3-341ED48DAA8CQ52430592-8E5DD612-F728-4EDA-B6A0-3384E43C2058Q56901675-F68EB607-3370-4751-B066-5A56651C7032
P2860
Good manufacturing practice production of adenoviral vectors for clinical trials.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Good manufacturing practice production of adenoviral vectors for clinical trials.
@ast
Good manufacturing practice production of adenoviral vectors for clinical trials.
@en
type
label
Good manufacturing practice production of adenoviral vectors for clinical trials.
@ast
Good manufacturing practice production of adenoviral vectors for clinical trials.
@en
prefLabel
Good manufacturing practice production of adenoviral vectors for clinical trials.
@ast
Good manufacturing practice production of adenoviral vectors for clinical trials.
@en
P356
P1433
P1476
Good manufacturing practice production of adenoviral vectors for clinical trials.
@en
P2093
Monika Lusky
P304
P356
10.1089/HUM.2005.16.281
P577
2005-03-01T00:00:00Z